The Ovarian Cancer Research Alliance offers specialized services and support to help ovarian cancer patients find a community ...

Acrivon Therapeutics, Inc. ("Acrivon” or "Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company ...

Penn Ovarian Cancer Research Center and Basser Center for BRCA, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States ...

"A highlight of the third quarter was the presentation of our validating COM701, COM902, pembrolizumab combination data in heavily pre-treated platinum resistant ovarian cancer (PROC ... more fully ...

A new study finds that pathogenic germline variants (PGVs) in cancer predisposition genes like BRCA1 and BRCA2 increase the risk of multiple ...

Given in combination with chemo, the Zynyz regimen reduced the risk of disease progression ... phase 1b study reported at ESMO. Incyte is highlighting the ovarian cancer cohort of 37 evaluable ...

Bonnie Qin, PhD, assistant professor at Rutgers Cancer institute, discusses factors that may influence adherence to dietary guidelines and improve survival for Black women with ovarian cancer.

Daly, MD, PhD, FACP, Fox Chase Cancer Center, Chair of the NCCN Guidelines Panel for Genetic/Familial High-Risk Assessment: ...

Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...

This review analyzed the factors of ovarian reserve, cyst laterality, size and location, patient age and prior surgical procedures. Based on these factors, the authors recommend three distinct ...

with a high risk of recurrence. Furthermore, medical therapy of ovarian cancer impacts quality of life owing to the common occurrence of chemotherapy side effects, such as alopecia, neurotoxicity ...

FRAX has been validated for fracture risk assessment for patients with cancer, with HRs indicating an association between ...